1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPharmacogenomics Grant Program is sponsored by Thermo Fisher Scientific. This program supports pharmacogenomics studies by providing free high-evidence content genotyping results using the Applied Biosystems™ Axiom™ PharmacoFocus™ Assay. Applicants need to describe how they would use the assay to drive pharmacogenomics discoveries.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Open to pharmacogenomic research in labs, academic hospitals, healthcare centers, and the pharmaceutical industry. Confirm the full requirements in the official notice before applying.
Pharmacogenomics Grant Program is funded by Thermo Fisher Scientific. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
America's Seed Fund powered by NSF reopened for FY2026 with two parallel solicitations: NSF 26-510 for deep technologies and a new pilot, NSF 26-511, dedicated to scientific instrumentation. Project Pitch is the mandatory first gate, the first full-proposal deadline is July 27, 2026, and Phase I runs up to $305K. Here is how the topic-agnostic NSF model differs from agency-directed SBIR — and how to use the new pilot.
Read articleNSF restarted its SBIR/STTR programs on May 31, 2026 after a multi-month hiatus, with a $250 million FY26 allocation, a Project Pitch portal reopen on June 2, and a first full-proposal deadline of July 27, 2026. The big structural changes: a new Strategic Breakthrough tier that extends invited Phase II companies up to $30 million, and a $40 million pilot for next-generation scientific instrumentation. Phase I tops out at $305K, Phase II at $1.25M, with November 4 and March 4, 2027 windows behind the July 27 first deadline. For deep-tech startups that watched the NIH SBIR omnibus go dark and DARPA pull back on conventional Phase II slots, this is the most consequential reopening of the year — and the Strategic Breakthrough tier is the first time NSF has competed directly with venture capital at growth-stage check sizes.
Read articleThe National Science Foundation reopened SBIR/STTR with $250M, a July 27 first deadline, $305K Phase I, $1.25M Phase II, and a new $40M scientific instrumentation pilot. Plus the $30M Strategic Breakthrough award. A strategic deep dive for deep-tech startups.
Read article